Vaccination against hepatitis a and b in patients with hiv
- 24 Downloads
Patients coinfected with HIV and viral hepatitis A or B are at increased risk for liver-related morbidity and mortality. Although vaccination is safe and effective in the general population, hepatitis A virus and hepatitis B virus transmission may continue in high-risk populations because vaccine response rates lag behind those seen in healthy populations. Poor immune response to vaccine, atypical markers of prior exposure, and difficulty reaching those at risk underlie the challenges facing clinicians and their HIV-infected patients.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 1.Centers for Disease Control and Prevention: HIV/AIDS Surveillance Report, 2004, vol 16. Atlanta: US Department of Health and Human Services, CDC; 2005.Google Scholar
- 2.Centers for Disease Control and Prevention: Guidelines for preventing opportunistic infections among HIV-infected persons—2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. MMWR Recomm Rep 2002, 51:1–52.Google Scholar
- 14.Centers for Disease Control and Prevention: Recommended adult immunization schedule—United States, October 2005-September 2006. MMWR 2005, 54:Q1–Q4.Google Scholar
- 23.Weissman S, Feucht C, Yarmohammadi H: Response to hepatitis A vaccination in HIV-positive patients [poster]. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco: Foundation for Retrovirology and Human Health; 2004:375. Poster 830.Google Scholar
- 24.Shire NJ, Welge JA, Sherman KE: Efficacy of inactivated hepatitis A vaccine in HIV-infected patients: a hierarchical Bayesian meta-analysis. Vaccine 2006, 24:272–279. Several studies have reported response rates to hepatitis A vaccine in HIV-infected patients approaching those in healthy volunteers; however, other studies have yielded a significantly abrogated rate of response in those with HIV. This random effects meta-analysis calculated an overall response rate approximating 64% by intention-to-treat analysis, underscoring the necessity of developing adjuvant immune-boosters or other methods for improving response in those with compromised immune systems.PubMedCrossRefGoogle Scholar
- 27.Fonseca MO, Pang LW, de Paula Cavalheiro N, et al.: Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. Vaccine 2005, 23:2902–2908. This double-blinded, controlled, randomized trial of HBV vaccine response rates in those with HIV demonstrated that response can be improved by doubling the primary dose of vaccine but that this effect is only seen in patients with relatively well-preserved immune function (CD4+ > 350).PubMedCrossRefGoogle Scholar
- 33.Cooper CL, Davis HL, Angel JB, et al.: CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults. AIDS 2005, 19:1473–1479. Cooper et al. showed a statistically significant improvement in response rate to vaccine against HBV in HIV-positive patients with CPG 7909 and double dose of vaccine. At 12 months, 100% of those in the adjuvant group had achieved protective levels of antibody (versus 63% of controls).PubMedCrossRefGoogle Scholar
- 34.Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep 1991, 40:1–25.Google Scholar
- 35.Taylor LE, Lai A, Schwartzapfel B, et al.: Analyzing the efficacy of standard hepatitis A and B vaccination schedules in HIV/HCV co-infected patients [poster]. 10th Conference on Retroviruses and Opportunistic Infections. Boston: Foundation for Retrovirology and Human Health; 2003:338. Poster 826.Google Scholar